EBV-related Lymphoma After Long-term Daratumumab Treatment: a Case Report

Overview

Journal Blood Cancer J

Date 2020 Nov 5

PMID 33149124

Citations 1

Authors

Ilse P G Verpoorte-Botden

Monique C Minnema

Reinier A P Raymakers

Affiliations

Soon will be listed here.

Citing Articles

Epstein-Barr Virus Driven Hodgkin's Lymphoma after a Short Course of Daratumumab Treatment for Relapsed Multiple Myeloma.

Mohammadi-Oroujeh M, Mehreen A, Grinblatt D Case Rep Hematol. 2023; 2023:6669174.

PMID: 38146540 PMC: 10749716. DOI: 10.1155/2023/6669174.

References

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

Jones R, Iempridee T, Wang X, Lee H, Mertz J, Kenney S . Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression. Clin Cancer Res. 2016; 22(19):4901-4912. PMC: 5050094. DOI: 10.1158/1078-0432.CCR-15-2242. View

Dharnidharka V, Webster A, Martinez O, Preiksaitis J, Leblond V, Choquet S . Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016; 2:15088. DOI: 10.1038/nrdp.2015.88. View

Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H . Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol. 2018; . DOI: 10.1111/ejh.13164. View

Suzuki K, Dimopoulos M, Takezako N, Okamoto S, Shinagawa A, Matsumoto M . Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018; 8(4):41. PMC: 5928154. DOI: 10.1038/s41408-018-0071-x. View

Plesner T, Arkenau H, Gimsing P, Krejcik J, Lemech C, Minnema M . Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016; 128(14):1821-1828. PMC: 5054695. DOI: 10.1182/blood-2016-07-726729. View

Lokhorst H, Plesner T, Laubach J, Nahi H, Gimsing P, Hansson M . Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N Engl J Med. 2015; 373(13):1207-19. DOI: 10.1056/NEJMoa1506348. View

Thorley-Lawson D, Gross A . Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004; 350(13):1328-37. DOI: 10.1056/NEJMra032015. View

Dimopoulos M, San-Miguel J, Belch A, White D, Benboubker L, Cook G . Daratumumab plus lenalidomide and dexamethasone lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018; 103(12):2088-2096. PMC: 6269302. DOI: 10.3324/haematol.2018.194282. View

10.

Yang E, Webster Marketon J, Chen M, Lo K, Kim S, Glaser R . Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression. Brain Behav Immun. 2010; 24(7):1089-96. PMC: 2939213. DOI: 10.1016/j.bbi.2010.04.013. View

11.

Nash R, Dansey R, Storek J, Georges G, Bowen J, Holmberg L . Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant. 2003; 9(9):583-91. PMC: 2956744. DOI: 10.1016/s1083-8791(03)00228-3. View

12.

Plesner T, Arkenau H, Gay F, Minnema M, Boccadoro M, Moreau P . Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. Br J Haematol. 2019; 186(3):e35-e39. DOI: 10.1111/bjh.15879. View

13.

Usmani S, Weiss B, Plesner T, Bahlis N, Belch A, Lonial S . Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016; 128(1):37-44. PMC: 4937359. DOI: 10.1182/blood-2016-03-705210. View

14.

Palumbo A, Chanan-Khan A, Weisel K, Nooka A, Masszi T, Beksac M . Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 375(8):754-66. DOI: 10.1056/NEJMoa1606038. View

15.

Frerichs K, Bosman P, Nijhof I, Zweegman S, van de Donk N . Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. Clin Lymphoma Myeloma Leuk. 2018; 19(1):e9-e11. PMC: 7104728. DOI: 10.1016/j.clml.2018.10.002. View

16.

McCarthy P, Owzar K, Hofmeister C, Hurd D, Hassoun H, Richardson P . Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012; 366(19):1770-81. PMC: 3744390. DOI: 10.1056/NEJMoa1114083. View